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YMethods: The REDUCE-HTN trial is a prospective, multicenter, single-arm study.
Patients were required to have ofﬁce-based systolic blood pressure (BP) 160 mmHg
despite compliance with 3 antihypertensive medications at maximally tolerated
doses. The primary efﬁcacy endpoints were the 6-month reductions in ofﬁce-based
systolic and diastolic BPs, and reductions in systolic and diastolic BP as measured by
24-hour ambulatory monitoring. Acute safety (ie, freedom from renal artery dissection
or perforation requiring stenting or surgery, renal artery infarction or embolus, cere-
brovascular accident, myocardial infarction, or sudden cardiac death at the time of the
procedure) and long-term safety, including renal artery patency and renal function,
were assessed.
Results: Mean baseline ofﬁce BP was 182.418.4/100.114.0 mmHg among
enrolled patients (N¼146; age 58.510.5 years, 61% men, 27.4% with type 2 dia-
betes). No patients experienced any of the prespeciﬁed acute safety events. Among 139
patients with 6 month data, mean ofﬁce BP was reduced to 157.723.8/
89.415.7 mmHg; a reduction of 24.622.3/10.312.9 mmHg (p<0.0001). Mean
baseline ambulatory BP was 153.015.1/87.513.2 mmHg (n¼103); at 6 months it
was reduced by 8.514.6/5.99.2 mmHg (n¼67; p<0.0001). Renal artery patency by
duplex ultrasound at 6 months was 99.1%. Mean estimated glomerular ﬁltration rate
(eGFR) changed -0.916.5 at 6 months, and 11% of patients (15/136) had a
reduction in eGFR >25%. Six-month results for the full cohort of enrolled patients are
expected to be available at the time of presentation.
Conclusions: Primary endpoint results from the REDUCE-HTN trial demonstrate
that the Vessix System is an efﬁcacious method for treating resistant hypertension. No
acute safety endpoint events were observed and 6-month patency and renal function
results are favorable.
CRT-608*
Pooled 3-Year Symplicity Htn-1 and Symplicity Htn-2 Results and Diabetes Subgroup
Analysis
Richard Katholi,1 Murray Esler,2 Henry Krum,3 Krishna Rocha-Singh,1
Markus Schlaich,2 Michael Böhm,4 Felix Mahfoud4
1Prairie Education and Research Cooperative, Springﬁeld, IL; 2Baker IDI Heart and
Diabetes Institute, Melbourne, Australia; 3Monash University, Melbourne, Australia;
4Universitätsklinium des Saarlandes, Homburg, Germany
Background: Treatment resistant hypertension (rHTN) is deﬁned as uncontrolled
blood pressure despite use of 3 antihypertensive drugs including a diuretic. The
sympathetic nervous system plays an important role in the pathogenesis of hyper-
tension. The Symplicity renal denervation system uses a percutaneous approach to
deliver low-power radiofrequency energy to interrupt the efferent sympathetic and
afferent renal nerves. Up to 3 year follow-up of pooled patient level data are available to
evaluate renal denervation (RDN) efﬁcacy and safety, including patients with type II
diabetes mellitus (DM).
Methods: The Symplicity HTN-1 and Symplicity HTN-2 prospective, multicenter
trials enrolled rHTN subjects with a systolic BP (SBP) 160 mm Hg; (150 mm
Hg for DM subjects). Subjects remained on their antihypertensive drugs for 6
months after which changes were allowed as clinically indicated. A subset of subjects
in Symplicity HTN-1were consented to 3 years; all subjects randomized to im-
mediate RDN on Symplicity HTN-2 were followed to 3 years post-RDN. Change
from baseline BP was measured at each follow-up and all safety events were
evaluated.
Results: Baseline characteristics of 128 subjects followed through 3 years include
mean age, 58 years; 34% DM, 38% female, and body mass index of 32 kg/m2. Mean
baseline SBP was 175.7  14.1 mm Hg and was reduced by 24.6  22.7 mm Hg at 6
months (p<0.01). This BP reduction was sustained at 3 years with a mean drop of
32.2  19.7 mm Hg (p<0.01). DM and non-DM subjects had similar baseline SBP
and experienced a similar and signiﬁcant reduction in SBP at 3 years (-30.0 mm Hg vs
-33.3 mm Hg, respectively, p<0.001 compared with baseline, p¼0.37 between DM
and non-DM subjects). Procedure-related adverse events included 2 dissections (1
before radiofrequency energy was delivered), and 1 access site hematoma. Serious
adverse events included 6 deaths, 4 renal failure cases (all resolved), and 1 stenosis
requiring stenting.
Conclusions: The data indicates that treatment of rHTN with the Symplicity catheter
provides safe and sustained reductions in SBP through 3 years. The reduction in SBP
was similar in both DM and non DM subjects.*Indicates iMPACT Trial Accepted for Oral PresentationCRT-610
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Background: A bipolar multi-electrode balloon catheter radiofrequency (RF) renal
denervation system offers advantages of short procedure time and low power to
minimize risk of non-target tissue thermal injury. We report a preclinical safety study
of a 7 French (F) system in a domestic swine model.
Methods: The 7F device was used to treat the renal arteries of 20 pigs, with over-
lapping treatments in the proximal 12 mm to mimic clinical balloon overlap. Each
histopathology cohort (30 & 90 day follow-up) had 4 RF-treated and 3 sham-treated
(no RF energy delivered) pigs and response of artery and surrounding nerves to
bilateral treatment was examined (28 arteries). Scanning electron microscopy was used
to examine the renal artery ﬂow surface for endothelialization, with unilateral whole
artery treatment with proximal overlap: RF on one side and sham on the other (3 pigs/
cohort; 12 arteries). Treatment duration was 30 seconds. Animals received 2 to 3
treatments per artery depending on artery length. Histology on all 40 kidneys and
assessment for non-target injury was undertaken in all 20 pigs.
Results: Renal artery injury was transmural and segmental, with variable percentages
of the circumference (<10% to >90%, typically 30-50%) demonstrating overlying
nerve injury and associated segmental neointimal hyperplasia. No increase in thermal
injury was observed in overlapped vs single-treatment segments. At 30 days, “islands”
of necrotic media remained, but at 90 days healing was essentially complete with
mature replacement ﬁbrosis. Inﬂammatory activity was mild at 30 days and minimal by
90 days. Maximum lumen stenosis (all sections, both time points) was 17.7%, he-
modynamically trivial, and typically <10%. Endothelialization was focally incomplete
at 30 days, but completely conﬂuent at 90 days. Sham-treated arteries showed only
mild focal mechanical injury, which was also seen with thermal treatment. Kidney
histology demonstrated no injury, and there was no injury to renal veins, ureters,
adrenal glands, psoas muscles, peritoneum or intestines.
Conclusion: Safety of the Boston Scientiﬁc Vessix renal denervation system in 7F
conﬁguration was demonstrated for both single and overlap treatment.
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Background: Intra-aortic balloon pumping (IABP) is the most frequently utilized
form of temporary mechanical support in cardiogenic shock. Withdrawal of IABP
support occasionally precipitates hemodynamic compromise or collapse such that
IABP reinsertion is considered or performed. The outcome of patients undergoing
IABP reinsertion has not been formally studied.
Methods: Using the MedStar Washington Hospital Center Cardiac Care Unit
(CCU) database, we identiﬁed a population of patients presenting with cardiogenic
shock who required IABP reinsertion after failed wean. As a control we identiﬁed a
matched population of patients who had received only a single IABP for cardiogenic
shock. The primary outcome investigated was in-hospital mortality. Secondary out-
comes included the utilization of other temporary or permanent methods of cardiac
support, transplant, and discharge to hospice and a composite thereof.
